Home
NanoAlvand

NanoAlvand Market Share Analysis for July 2026

nanoalvand

Industry: N/A

Domainnanoalvand.com

Year Founded2011

Employees501 - 1000

Annual Revenue$15M - $25M

NanoAlvand

NanoAlvand (including company regionals)

nanoalvand.com

See more website traffic and engagement information

NanoAlvand Revenue up to July 2026 is 15M - 25M

revenue generated by NanoAlvand top domains

NanoAlvand top domains revenue over 3 years

Revenue for NanoAlvand top domains

nanoalvand.com15M - 25M

See more with Sales Intelligence

Total visits to NanoAlvand's top domains

Understand NanoAlvand market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

nanoalvand.com11.4K

See more with Sales Intelligence

Avg. visit duration in NanoAlvand's top domains

Analyze NanoAlvand engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

nanoalvand.com--

See more with Sales Intelligence

Avg. pageviews on NanoAlvand's top domains

See how NanoAlvand keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

nanoalvand.com1.02

See more with Sales Intelligence

NanoAlvand top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by NanoAlvand

These are the website technologies, by industry, used by NanoAlvand top domains

Widget (3)

Google Maps

Advertising (2)

PubMatic

Content Management System (2)

WordPress

eCommerce (2)

Swap

More Technologies

3

See all

News & Signals from NanoAlvand

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNanoAlvand Pharmaceutical Co. launches Venetoclax.At NanoAlvand, NanoAlvand Pharmaceutical Co. is proud to present Venetoclax, a selective BCL-2 inhibitor that has transformed treatment paradigms in hematology.

NewsNanoAlvand Pharmaceutical Co. launches Amitzo, Temozolomide 100 mg powder for solution.At NanoAlvand, NanoAlvand Pharmaceutical Co. is proud to introduce Amitzo(R), Temozolomide 100 mg powder for solution, its latest advancement in the oncology portfolio.

NewsNanoAlvand Pharmaceutical Co. launches Adriax.NanoAlvand is proud to expand its oncology portfolio with the launch of Adriax(R), a solution formulation of Doxorubicin Hydrochloride, available in 10 mg and 50 mg injectable vials.